Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec/Insulin Aspart Biosimilar (22011) vs Ryzodeg in Type 2 Diabetes
NCT05802862Phase 3Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jul 2023
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec, insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Sunshine Lake Pharma. Started Jul 2023; status: completed.
02
Drugs
insulin degludecinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05802862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802862.